Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Effect of bergamot on lipid profile in humans: A systematic review

  • Lamiquiz-Moneo, Itziar
  • Giné-González, Jaume
  • Alisente, Sonsoles
  • Bea, Ana M.
  • Pérez-Calahorra, Sofía
  • Marco-Benedi, Victoria
  • Baila-Rueda, Lucía
  • Jarauta, Estíbaliz
  • Cenarro, Ana
  • Civeira, Fernando
  • Mateo-Gallego, Rocío
Dyslipidemia is a well-established modifiable cardiovascular risk. Although statins can reduce LDLc by 50-60%, less than 20% of patients with high risk of CVD achieve LDL targets. The aim of this systematic review is to evaluate the effect of the nutraceutical, bergamot (Citrus bergamia), on lipid parameters in humans. PubMed, Embase, Cochrane Library, and Google Scholar databases were searched for interventional and observational studies investigating the effect of bergamot on lipid profile in humans. This systematic review retrieved a total of 442 studies of which 12 articles fulfilled the eligibility criteria and were included in the qualitative synthesis. Based on data, 75% of studies showed a significant decrease in total cholesterol, triglycerides and LDLc. The decrease in total cholesterol varied from 12.3% to 31.3%, from 7.6% to 40.8% in LDLc and from 11.5% to 39.5% in triglycerides. Eight trials reported HDLc increase after intervention with bergamot. Overall, a dose-dependent and possible synergistic effect when administering with statins can be deducted from these trials. It is essential to point out that studies had heterogeneous designs and scientific quality of studies was quite limited. Promising findings reveal an alternative therapeutic option in dyslipidemia management with bergamot supplementation, especially in subjects with statins intolerance.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE

  • Jarauta, E.
  • Pérez-Ruiz, M. R.
  • Pérez-Calahorra, S.
  • Mateo-Gallego, R.
  • Cenarro, A.
  • Cofán, M.
  • Ros, E.
  • Civeira, F.
  • Tejedor, M. T.
Background: A substantial proportion of individuals clinically diagnosed as familial hypercholesterolemia (FH) do not carry pathogenic mutations in candidate genes. Whether in them the high cholesterol trait is transmitted monogenically has not been studied. Objectives: We assessed the inheritance pattern, penetrance, and expression of high low-density lipoprotein (LDL)-cholesterol (LDLc) in families with genetic hypercholesterolemia (GH) without known causative mutations (non-FH-GH). Methods: The study included probands with a clinical diagnosis of FH and their families attending 2 lipid clinics in Spain. Inclusion criteria for probands were LDLc >95th percentile, triglycerides 90th percentile, >5 points in the Dutch Lipid Clinic Network criteria score, and absence of mutations in LDLR, APOB, PCSK9 or APOE. Eleven FH families with a LDLR mutation were also examined for comparison. Results: We analyzed 49 non-FH-GH probands and 277 first-and second-degree relatives. LDLc was >90th percentile in 37.8% of blood relatives, at concentrations similar to those of probands. LDLc had a normal distribution in non-FH-GH families, in contrast with a bimodal distribution in FH families. When a dominant model was tested, family-based association tests gave much lower heritability values for total cholesterol and LDLc in non-FH-GH (0.39 and 0.32, respectively) than in FH (0.78 and 0.61, respectively). Conclusions: Non-FH-GH families have a milder lipid phenotype than genetically defined FH. The heritage pattern of LDLc in non-FH-GH does not fit with a monogenic disorder. Our findings support the concept that most non-FH-GHs are polygenic hypercholesterolemias.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia

  • Bea, Ana M.
  • Civeira, Fernando
  • Jarauta, Estíbaliz
  • Lamiquiz-Moneo, Itziar
  • Pérez-Calahorra, Sofía
  • Marco-Benedí, Victoria
  • Cenarro, Ana
  • Mateo-Gallego, Rocío
Introduction and objectives The equations used in the general population to calculate cardiovascular risk are not useful in genetic hypercholesterolemia (GH). Carotid plaque detection has proved useful in cardiovascular prediction and risk reclassification but there have been no studies of its usefulness in GH. The aim of this study was to determine the association between the presence of carotid artery plaque and the occurrence of cardiovascular events in patients with GH. Methods This study included 1778 persons with GH. The mean follow-up until the occurrence of cardiovascular events was 6.26 years. At presentation, the presence of carotid artery plaque was studied by high-resolution ultrasound. Results Carotid artery plaque was found in 661 (37.2%) patients: 31.9% with familial hypercholesterolemia, 39.8% with familial combined hyperlipidemia, 45.5% with dysbetalipoproteinemia, and 43.2% with polygenic hypercholesterolemia. During follow-up, 58 patients had a cardiovascular event. Event rates were 6354/100 000 (95%CI, 4432.4-8275.6) in the group with plaque and 1432/100 000 (95%CI, 730.6-2134.3) in the group without plaque, with significant differences between the 2 groups (P < .001). The relative risk of an event was 4.34 (95CI%, 2.44-7.71; P < .001) times higher in patients with plaque and was 2.40 (95%CI, 1.27-4.56; P = .007) times higher after adjustment for major risk factors. The number of carotid artery plaques was positively associated with the risk of cardiovascular events. Conclusions Most cardiovascular events occur in a subgroup of patients who can be identified by carotid plaque detection. These results support the use of plaque screening in this population and should help in risk stratification and treatment in GH. Resumen Introducción y objetivos Las ecuaciones de riesgo empleadas en población general no son de utilidad en hipercolesterolemias genéticas (HG). Las placas carotídeas se han demostrado útiles en la predicción cardiovascular y la reclasificación del riesgo. Su utilidad en HG no se ha estudiado y es el objetivo del estudio. Métodos Se incluyó a 1.778 sujetos con HG y una media de seguimiento de 6,26 años hasta la aparición de eventos cardiovasculares, en los que al inicio se estudió la presencia de placas en carótidas por ecografía de alta resolución. Resultados Se encontraron placas en 661 (37,2%) sujetos: el 31,9% con hipercolesterolemia familiar, el 39,8% en hiperlipemia familiar combinada, el 45,5% en disbetalipoproteinemia y el 43,2% en hipercolesterolemia poligénica. Durante el seguimiento, 58 pacientes sufrieron un evento cardiovascular. La tasa de eventos fue 6.354/100.000 (IC95%, 4.432,4-8.275,6) en el grupo con placa y 1.432/100.000 (IC95%, 730,6-2.134,3) en el grupo sin placa, con diferencia significativa entre ambos grupos (p < 0,001). El riesgo de sufrir un evento de los sujetos con placa fue 4,34 (IC95%, 2,44-7,71; p < 0,001) veces superior en presencia de placa y 2,40 (IC95%, 1,27-4,56; p = 0,007) veces superior tras ajustar por los principales factores de riesgo. El número total de placas se asoció positivamente con el riesgo de eventos. Conclusiones La detección de placas carotídeas identifica a un subgrupo de pacientes que concentran la mayoría de los eventos cardiovasculares. Estos resultados respaldan la utilización de la detección de placas en esta población y deben ayudar en la estratificación del riesgo y la planificación del tratamiento en las HG.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Asociación de la presencia de placa carotídea en la aparición de eventos cardiovasculares en pacientes con hipercolesterolemias genéticas [Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia]

  • Bea, Ana M.
  • Civeira, Fernando
  • Jarauta, Estíbaliz
  • Lamiquiz-Moneo, Itziar.
  • Pérez-Calahorra, Sofía
  • Marco-Benedí, Victoria
  • Cenarro, Ana
  • Mateo-Gallego, Rocío
Introduction and objectives The equations used in the general population to calculate cardiovascular risk are not useful in genetic hypercholesterolemia (GH). Carotid plaque detection has proved useful in cardiovascular prediction and risk reclassification but there have been no studies of its usefulness in GH. The aim of this study was to determine the association between the presence of carotid artery plaque and the occurrence of cardiovascular events in patients with GH. Methods This study included 1778 persons with GH. The mean follow-up until the occurrence of cardiovascular events was 6.26 years. At presentation, the presence of carotid artery plaque was studied by high-resolution ultrasound. Results Carotid artery plaque was found in 661 (37.2%) patients: 31.9% with familial hypercholesterolemia, 39.8% with familial combined hyperlipidemia, 45.5% with dysbetalipoproteinemia, and 43.2% with polygenic hypercholesterolemia. During follow-up, 58 patients had a cardiovascular event. Event rates were 6354/100 000 (95%CI, 4432.4-8275.6) in the group with plaque and 1432/100 000 (95%CI, 730.6-2134.3) in the group without plaque, with significant differences between the 2 groups (P <.001). The relative risk of an event was 4.34 (95CI%, 2.44-7.71; P <.001) times higher in patients with plaque and was 2.40 (95%CI, 1.27-4.56; P =.007) times higher after adjustment for major risk factors. The number of carotid artery plaques was positively associated with the risk of cardiovascular events. Conclusions Most cardiovascular events occur in a subgroup of patients who can be identified by carotid plaque detection. These results support the use of plaque screening in this population and should help in risk stratification and treatment in GH. Full English text available from: www.revespcardiol.org/en